Retrospective Study of Implants With Peri-implantitis Surgically Treated Using Enamel Matrix Derivative (EMD)

North Dallas Dental Health

Status: Completed

Conditions: Determination of Beneficial Effect of Using Enamel Matrix Derivative During Implant Treatment

Treatments: Procedure: peri-implantitis surgery with enamel matrix derivative

Study type: Observational

Funder types: Other

Identifiers

NCT05419102

EMD Implant 1

Details and patient eligibility

About

The existing records of a private practice limited to the practice of periodontology were reviewed to locate patients who had been diagnosed with peri-implantitis (failing dental implant) and had been surgically treated utilizing enamel matrix derivative (Commercially available FDA product Emdogain sold by Straumann USA). Various clinical factors were gathered from the existing records. Some of the factors recorded were: retention of the implant, presence of bleeding, presence of further damage, and presence of inflammation. All patients had signed an informed consent for treatment and the anonymous use of their data for research purposes. All HIPA requirements were followed.

Full description

See brief summary.

Enrollment: 34 patients

Sex: All

Ages: 18 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• all adult patients of record who presented with existing peri-implantitis that was clinically deemed treatable (the implant was not considered hopeless.)

Exclusion criteria

• none except for routine medical contraindications for periodontal surgery